We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




RNAi Engineering May Prevent Mad Cow

By Biotechdaily staff writers
Posted on 31 Mar 2006
By "knocking down” the expression of disease-causing genes in a cloned goat fetus, researchers may have developed a way to prevent bovine spongiform encephalopathy (BSE), known as mad cow disease. More...


The researchers used genetic engineering to produce a goat cell line in which the gene encoding for prion protein (PrP) was targeted for silencing by RNA interference (RNAi). Cells from this line were then used for nuclear transfer to produce a transgenic goat fetus that showed a greater than 90% knock-down of PrP. In earlier studies, silencing the PrP gene in mice made them resistant to prion-mediated diseases, such as BSE. The results of the new research were published in the March 22 issue of the Proceedings of the [U.S.] National Academy of Sciences.

The same technology may be able to be used in cattle to prevent mad cow and other serious diseases, according to the researcher team, whose members are from Texas A&M's College of Veterinary Medicine & Biomedical Sciences (College Station, TX, USA) and the Howard Hughes Medical Institute's Cold Spring Harbor Laboratory (Cold Spring Harbor, NY, USA).

BSE is a fatal brain-wasting disease, first identified in 1986. It affects a cow's nervous system and causes the animal to lose much of its movement before it eventually dies. More than 180,000 cases of BSE have been confirmed worldwide, including recent cases in the United States. The disease can be passed to humans, and more than 100 such cases have been confirmed, most of those in the United Kingdom.

"The next step is to try and avoid the cloning process--to skip that process if possible in developing the disease-resistant animals,” explained Dr. Mark Westhusin, one of the researchers. "That's where more research is going to be needed and where the process goes from here.” Dr. Westhusin has been involved in several cloning "firsts,” including the cloning of a cat in 2002 and a white-tailed deer in 2004.



Related Links:
Texas A&M
HH Medical Institute's Cold Spring Harbor

New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Total Laboratory Automation Solution
SATLARS Mini T8
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.